Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

NASDAQ:CARA opened at $0.31 on Thursday. Cara Therapeutics has a 1 year low of $0.24 and a 1 year high of $1.31. The stock’s fifty day moving average price is $0.29 and its two-hundred day moving average price is $0.38. The company has a market cap of $16.74 million, a P/E ratio of -0.17 and a beta of 0.68.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CARA. XTX Topco Ltd bought a new position in shares of Cara Therapeutics in the third quarter valued at approximately $29,000. FMR LLC boosted its holdings in Cara Therapeutics by 18.5% in the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the period. Finally, Disciplined Growth Investors Inc. MN grew its position in shares of Cara Therapeutics by 6.6% during the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 120,660 shares in the last quarter. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.